{
    "ticker": "CARA",
    "name": "Cara Therapeutics, Inc.",
    "description": "Cara Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for pain and pruritus (itch). Founded in 2004 and headquartered in Shelton, Connecticut, Cara is pioneering a new class of therapies targeting the body's peripheral and central nervous systems. The company\u2019s lead product, KORSUVA, is an injectable formulation of difelikefalin, which has received approval for the treatment of moderate to severe pruritus in patients with chronic kidney disease undergoing hemodialysis. Cara's mission is to improve the quality of life for patients suffering from pain and itch through the development of novel therapies that address unmet medical needs. The company's pipeline also includes oral formulations of difelikefalin for various indications. Cara Therapeutics is committed to advancing its research and development efforts to bring forth effective solutions while ensuring high standards of safety and efficacy. With a strong focus on innovation and a dedication to patient care, Cara is well-positioned to make a significant impact in the biopharmaceutical industry.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Shelton, Connecticut, USA",
    "founded": "2004",
    "website": "https://www.caratherapeutics.com",
    "ceo": "D. Barry McGowan",
    "social_media": {
        "twitter": "https://twitter.com/CaraTherapeutics",
        "linkedin": "https://www.linkedin.com/company/cara-therapeutics"
    },
    "investor_relations": "https://investors.caratherapeutics.com",
    "key_executives": [
        {
            "name": "D. Barry McGowan",
            "position": "CEO"
        },
        {
            "name": "Robert J. E. L. P. M. O'Connor",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Prescription Medications",
            "products": [
                "KORSUVA"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cara Therapeutics, Inc. | Innovative Pain and Itch Treatments",
        "meta_description": "Explore Cara Therapeutics, Inc., a leader in developing innovative therapies for pain and itch. Learn about our products, pipeline, and commitment to patient care.",
        "keywords": [
            "Cara Therapeutics",
            "KORSUVA",
            "biotechnology",
            "pain management",
            "pruritus",
            "chronic kidney disease"
        ]
    },
    "faq": [
        {
            "question": "What does Cara Therapeutics focus on?",
            "answer": "Cara Therapeutics focuses on developing innovative treatments for pain and pruritus."
        },
        {
            "question": "What is KORSUVA?",
            "answer": "KORSUVA is an injectable formulation approved for the treatment of moderate to severe pruritus in patients with chronic kidney disease."
        },
        {
            "question": "Where is Cara Therapeutics headquartered?",
            "answer": "Cara Therapeutics is headquartered in Shelton, Connecticut, USA."
        },
        {
            "question": "When was Cara Therapeutics founded?",
            "answer": "Cara Therapeutics was founded in 2004."
        }
    ],
    "competitors": [
        "AMGN",
        "NVS",
        "VRTX"
    ],
    "related_stocks": [
        "ABBV",
        "BMY",
        "PFE",
        "GILD"
    ]
}